Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
13.54
+0.28 (2.11%)
Nov 4, 2024, 4:00 PM EST - Market closed
Avalo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.81 | 1.92 | 18.05 | 5.4 | 6.7 | 6.75 | Upgrade
|
| Revenue Growth (YoY) | -95.24% | -89.34% | 234.40% | -19.42% | -0.76% | -3.96% | Upgrade
|
| Cost of Revenue | 3.91 | 9.95 | 25.99 | 50.12 | 25.24 | 11.63 | Upgrade
|
| Gross Profit | -3.1 | -8.02 | -7.94 | -44.72 | -18.54 | -4.88 | Upgrade
|
| Selling, General & Admin | 12.89 | 10.3 | 13.91 | 24.66 | 19.76 | 11.61 | Upgrade
|
| Research & Development | 6.21 | 5.12 | 8.05 | 11.21 | 7.26 | 1.17 | Upgrade
|
| Operating Expenses | 19.1 | 15.42 | 22 | 37.41 | 28.76 | 14.11 | Upgrade
|
| Operating Income | -22.2 | -23.44 | -29.94 | -82.13 | -47.29 | -18.99 | Upgrade
|
| Interest Expense | -1.47 | -3.42 | -4.17 | -2.39 | - | - | Upgrade
|
| Interest & Investment Income | 1.14 | - | - | - | 0.05 | 0.12 | Upgrade
|
| Other Non Operating Income (Expenses) | 17.87 | -0.76 | -0.02 | -0.02 | 0.41 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | -4.66 | -27.62 | -34.13 | -84.55 | -46.84 | -18.9 | Upgrade
|
| Merger & Restructuring Charges | - | - | -7.5 | - | - | - | Upgrade
|
| Impairment of Goodwill | -3.91 | -3.91 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 5.21 | 0.05 | Upgrade
|
| Legal Settlements | - | - | - | - | - | 1.6 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 1.26 | Upgrade
|
| Pretax Income | -36.21 | -31.53 | -41.63 | -84.55 | -67.18 | -15.99 | Upgrade
|
| Income Tax Expense | 0.01 | 0.01 | 0.03 | -0.2 | -2.79 | 0.28 | Upgrade
|
| Earnings From Continuing Operations | -36.22 | -31.54 | -41.66 | -84.35 | -64.38 | -16.27 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | -0.03 | 0.88 | 0.2 | Upgrade
|
| Net Income | -36.22 | -31.54 | -41.66 | -84.38 | -63.5 | -16.07 | Upgrade
|
| Net Income to Common | -36.22 | -31.54 | -41.66 | -84.38 | -63.5 | -16.07 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 1461.15% | 608.45% | 8.32% | 41.86% | 28.53% | 64.39% | Upgrade
|
| EPS (Basic) | -50.01 | -113.58 | -1062.65 | -2331.41 | -2489.12 | -809.74 | Upgrade
|
| EPS (Diluted) | -204.70 | -113.58 | -1062.65 | -2331.41 | -2489.12 | -809.74 | Upgrade
|
| Free Cash Flow | -32.09 | -30.84 | -26.85 | -71.01 | -40.6 | -19.4 | Upgrade
|
| Free Cash Flow Per Share | -44.30 | -111.04 | -684.81 | -1961.95 | -1591.55 | -977.20 | Upgrade
|
| Gross Margin | - | - | -43.98% | - | -276.70% | -72.28% | Upgrade
|
| Operating Margin | -2751.05% | -1218.50% | -165.86% | -1521.56% | -705.99% | -281.37% | Upgrade
|
| Profit Margin | -4488.60% | -1639.50% | -230.78% | -1563.10% | -947.90% | -238.10% | Upgrade
|
| Free Cash Flow Margin | -3976.08% | -1602.81% | -148.72% | -1315.39% | -606.09% | -287.34% | Upgrade
|
| EBITDA | -22.05 | -23.29 | -29.77 | -80.48 | -45.45 | -17.54 | Upgrade
|
| EBITDA Margin | - | - | -164.94% | - | - | -259.77% | Upgrade
|
| D&A For EBITDA | 0.15 | 0.16 | 0.17 | 1.66 | 1.84 | 1.46 | Upgrade
|
| EBIT | -22.2 | -23.44 | -29.94 | -82.13 | -47.29 | -18.99 | Upgrade
|
| EBIT Margin | - | - | -165.86% | - | - | -281.37% | Upgrade
|
| Revenue as Reported | 0.81 | 1.92 | 18.05 | 5.4 | 6.7 | 6.75 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.